Relay Therapeutics (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 187,163 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 187,163 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $16.97, for a total value of $3,176,156.11. Following the transaction, the chief financial officer owned 177,461 shares of the company’s stock, valued at approximately $3,011,513.17. This represents a 51.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

• On Thursday, May 14th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $12.86, for a total value of $227,840.62.
• On Tuesday, April 28th, Thomas Catinazzo sold 972 shares of Relay Therapeutics stock. The shares were sold at an average price of $14.79, for a total value of $14,375.88.
• On Tuesday, April 7th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $13.01, for a total value of $230,498.17.
• On Thursday, April 9th, Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock. The stock was sold at an average price of $15.00, for a total value of $27,000.00.

Relay Therapeutics Stock Performance

Shares of RLAY stock opened at $18.03 on Thursday. Relay Therapeutics, Inc. has a 1 year low of $3.03 and a 1 year high of $18.83. The firm has a market capitalization of $3.45 billion, a PE ratio of -11.49 and a beta of 1.75. The stock has a fifty day moving average of $14.40 and a two-hundred day moving average of $11.04.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $5.58 million. Equities research analysts predict that Relay Therapeutics, Inc. will post -1.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RLAY has been the topic of a number of recent analyst reports. Barclays boosted their price target on shares of Relay Therapeutics from $21.00 to $27.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Oppenheimer increased their price objective on shares of Relay Therapeutics from $14.00 to $18.00 and gave the company an “outperform” rating in a report on Tuesday, April 28th. Wall Street Zen upgraded shares of Relay Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Wells Fargo & Company boosted their target price on Relay Therapeutics from $17.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Finally, The Goldman Sachs Group upped their target price on Relay Therapeutics from $13.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Relay Therapeutics has a consensus rating of “Buy” and a consensus price target of $23.30.

Institutional Investors Weigh In On Relay Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of RLAY. SG Americas Securities LLC raised its holdings in shares of Relay Therapeutics by 591.7% in the 4th quarter. SG Americas Securities LLC now owns 220,949 shares of the company’s stock worth $1,869,000 after purchasing an additional 189,004 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in Relay Therapeutics during the third quarter worth approximately $399,000. Sanctuary Advisors LLC bought a new stake in Relay Therapeutics during the fourth quarter worth approximately $1,203,000. Commodore Capital LP boosted its holdings in Relay Therapeutics by 27.3% during the third quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock worth $88,740,000 after buying an additional 3,650,000 shares in the last quarter. Finally, Mayport LLC acquired a new position in Relay Therapeutics in the third quarter worth approximately $259,000. 96.98% of the stock is owned by institutional investors and hedge funds.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.